JP7621270B2 - シアリダーゼ耐性糖およびその調製および使用方法 - Google Patents

シアリダーゼ耐性糖およびその調製および使用方法 Download PDF

Info

Publication number
JP7621270B2
JP7621270B2 JP2021558537A JP2021558537A JP7621270B2 JP 7621270 B2 JP7621270 B2 JP 7621270B2 JP 2021558537 A JP2021558537 A JP 2021558537A JP 2021558537 A JP2021558537 A JP 2021558537A JP 7621270 B2 JP7621270 B2 JP 7621270B2
Authority
JP
Japan
Prior art keywords
mmol
equiv
fluoro
sialic acid
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529408A (ja
JP2022529408A5 (https=
Inventor
ウォン，チ－ヒューイ
ロー，ホン－ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of JP2022529408A publication Critical patent/JP2022529408A/ja
Publication of JP2022529408A5 publication Critical patent/JP2022529408A5/ja
Priority to JP2025005021A priority Critical patent/JP2025063181A/ja
Application granted granted Critical
Publication of JP7621270B2 publication Critical patent/JP7621270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021558537A 2019-04-05 2020-03-10 シアリダーゼ耐性糖およびその調製および使用方法 Active JP7621270B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005021A JP2025063181A (ja) 2019-04-05 2025-01-14 シアリダーゼ耐性糖およびその調製および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829736P 2019-04-05 2019-04-05
US62/829,736 2019-04-05
PCT/US2020/014608 WO2020205034A1 (en) 2019-04-05 2020-03-10 Sialidase-resistant saccharide and method of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005021A Division JP2025063181A (ja) 2019-04-05 2025-01-14 シアリダーゼ耐性糖およびその調製および使用方法

Publications (3)

Publication Number Publication Date
JP2022529408A JP2022529408A (ja) 2022-06-22
JP2022529408A5 JP2022529408A5 (https=) 2023-02-16
JP7621270B2 true JP7621270B2 (ja) 2025-01-24

Family

ID=72666761

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558537A Active JP7621270B2 (ja) 2019-04-05 2020-03-10 シアリダーゼ耐性糖およびその調製および使用方法
JP2025005021A Pending JP2025063181A (ja) 2019-04-05 2025-01-14 シアリダーゼ耐性糖およびその調製および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005021A Pending JP2025063181A (ja) 2019-04-05 2025-01-14 シアリダーゼ耐性糖およびその調製および使用方法

Country Status (9)

Country Link
US (2) US12384811B2 (https=)
EP (1) EP3947406A4 (https=)
JP (2) JP7621270B2 (https=)
KR (2) KR20260018203A (https=)
CN (1) CN115605491B (https=)
CA (1) CA3131096A1 (https=)
IL (1) IL286492B1 (https=)
TW (1) TWI749504B (https=)
WO (1) WO2020205034A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
TWI870591B (zh) 2020-05-08 2025-01-21 中央研究院 嵌合流感疫苗
BR112023000666A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115797A1 (ja) 2013-01-23 2014-07-31 第一三共株式会社 糖鎖修飾心房性ナトリウム利尿ペプチド
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0812695A (ja) * 1994-06-30 1996-01-16 Nisshin Oil Mills Ltd:The 新規シアル酸供与体
US7569376B2 (en) 2002-05-03 2009-08-04 Neose Technologies, Inc. Fucosyltransferase fusion protein
CA2441677A1 (en) 2003-05-09 2004-11-09 Adaltis Inc. Peptides and mixtures thereof for detecting antibodies to severe acute respiratory syndrome-associated coronavirus
US20090214590A1 (en) 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
DK3438131T3 (da) 2006-02-10 2022-04-11 Life Technologies Corp Oligosaccharidmodifikation og mærkning af proteiner
PT2170365T (pt) 2007-06-25 2016-07-12 Autoimmune Tech Llc Composições e métodos inibidores de influenza
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
RU2011111640A (ru) 2008-08-29 2012-10-10 Симфоген А/С (Dk) Антитела против cd5
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
HUE039100T2 (hu) 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
US20130005797A1 (en) 2010-03-18 2013-01-03 Merck Sharp & Dohme Corp. Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
EP2654787A1 (en) 2010-12-22 2013-10-30 Novavax, Inc. Modified influenza hemagglutinin proteins and uses thereof
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
WO2013067652A1 (en) 2011-11-10 2013-05-16 Beijing Advaccine Biotechnology Co., Ltd. Facilitator-dna combination vaccine
WO2014055474A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2015031166A1 (en) 2013-08-26 2015-03-05 Fred Hutchinson Cancer Research Center Compositions and methods for directed immunogen evolution and uses thereof
US9975925B2 (en) 2013-08-28 2018-05-22 Glaxosmithkline Biologicals S.A. Influenza antigens and antibodies
US10421802B2 (en) 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
CN105934441A (zh) 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
WO2015142671A2 (en) 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
CN104189897A (zh) 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2017062496A2 (en) 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
KR101873527B1 (ko) * 2016-09-02 2018-07-02 부산대학교 산학협력단 시알산 유도체를 포함하는 자궁내막증 예방 또는 치료용 조성물
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3056206A1 (en) 2017-03-15 2018-09-20 Polyneuron Pharmaceuticals Ag Glycopolymers sequestering carbohydrate-binding proteins
US20200231633A1 (en) 2017-07-19 2020-07-23 The Regents Of The University Of California MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products
AU2018312563A1 (en) 2017-08-01 2020-03-12 City Of Hope Anti-IL1RAP antibodies
CN111770991A (zh) 2017-12-18 2020-10-13 通用医疗公司 糖工程
US11191777B2 (en) 2018-06-20 2021-12-07 International Business Machines Corporation Antimicrobial guanidinium macromolecules with bacteria targeting moieties
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110713537B (zh) 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
KR20210061393A (ko) 2018-09-18 2021-05-27 유니버시테이트 젠트 치료용 나노입자 및 이의 사용 방법
WO2020077159A1 (en) 2018-10-10 2020-04-16 The Johns Hopkins University POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY
WO2020172072A1 (en) 2019-02-21 2020-08-27 The General Hospital Corporation Glycoengineering immunoglobulin e
WO2020198865A1 (en) 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
GB201908352D0 (en) 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
FR3098110B1 (fr) 2019-07-03 2022-02-04 Chanel Parfums Beaute Composition cosmétique solide
BR112022001185A2 (pt) 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
BR102019017792A2 (pt) 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
US20220387461A1 (en) 2019-09-04 2022-12-08 Victoria Link Ltd Cancer vaccine
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021174128A1 (en) 2020-02-26 2021-09-02 University Of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2
MX2022011142A (es) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
IL296426A (en) 2020-03-19 2022-11-01 Baseclick Gmbh Maran"im that underwent a change for the development of a component
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US20210316002A1 (en) 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
RU2720614C9 (ru) 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
KR20230005962A (ko) 2020-05-01 2023-01-10 니코데 테라퓨틱스 에이에스에이 베타코로나바이러스 예방 및 치료요법
TWI870591B (zh) 2020-05-08 2025-01-21 中央研究院 嵌合流感疫苗
IL298333A (en) 2020-05-20 2023-01-01 Alexandru Adrian Hennrich A viral assembly vector for a vaccine against the corona virus cell
CN116322732A (zh) 2020-06-17 2023-06-23 迪斯拉普申实验室公司 用治疗剂补充产品的组合物及其使用方法
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
RU2730897C1 (ru) 2020-07-01 2020-08-26 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) СПОСОБ ИСПОЛЬЗОВАНИЯ РЕКОМБИНАНТНЫХ БЕЛКОВ SARS-COV-2 В СОСТАВЕ ТЕСТ-СИСТЕМЫ ДЛЯ ИММУНОФЕРМЕНТНОГО АНАЛИЗА С ОПРЕДЕЛЕНИЕМ УРОВНЕЙ АНТИТЕЛ КЛАССОВ IgM, IgG, IgA В СЫВОРОТКЕ/ПЛАЗМЕ КРОВИ БОЛЬНЫХ COVID-19
WO2022047401A1 (en) 2020-08-31 2022-03-03 The University Of Chicago Targeted, intracellular delivery of therapeutic peptides using supramolecular nanomaterials
CN112626124B (zh) 2020-10-15 2023-04-11 广州达博生物制品有限公司 一种病毒保存试剂
BR112023005961A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Molécula de ácido nucleico modificada, vacina combinada, nanopartícula, nanocluster de mrna, método para prevenir ou tratar uma infecção por coronavírus, método para reforço de uma resposta imune adaptativa, peptídeo imunogênico e composição imunogênica
BR112023000666A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
JP2024517711A (ja) 2021-04-29 2024-04-23 ノバルティス アーゲー 高シアル酸付加細胞
CN113265050B (zh) 2021-04-30 2022-08-23 浙江大学 一种可降解高分子材料和自组装纳米复合物及应用
GB202111759D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
US20250195639A1 (en) 2021-10-20 2025-06-19 The Regents Of The University Of California Multi-epitope mrna sars-cov-2 vaccine for boosting immunity through the activation of cd4 and cd8 t cells as well as b lymphocytes
WO2023129928A2 (en) 2021-12-27 2023-07-06 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
CN116478948A (zh) 2023-03-01 2023-07-25 中山大学 一种生成高唾液酸化蛋白药物的细胞工程方法
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
WO2024215616A2 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting vaccines
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115797A1 (ja) 2013-01-23 2014-07-31 第一三共株式会社 糖鎖修飾心房性ナトリウム利尿ペプチド
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Angewandte Chemie International Edition，2019年01月25日，58(12)，3814-3818，DOI: 10.1002/anie.201812963
Journal of the American Chemical Society，2007年，129(35)，10630-10631，DOI: 10.1021/ja072687u
Journal of the American Chemical Society，2019年04月15日，141(16)，6484-6488，DOI: 10.1021/jacs.9b01991
Tetrahedron，1987年，43(24)，5919-5928，DOI: 10.1016/S0040-4020(01)87797-8

Also Published As

Publication number Publication date
US20220267363A1 (en) 2022-08-25
WO2020205034A1 (en) 2020-10-08
US12384811B2 (en) 2025-08-12
JP2022529408A (ja) 2022-06-22
IL286492A (en) 2021-12-01
CA3131096A1 (en) 2020-10-08
TW202104272A (zh) 2021-02-01
US20260008803A1 (en) 2026-01-08
KR102920761B1 (ko) 2026-02-02
KR20210137485A (ko) 2021-11-17
EP3947406A1 (en) 2022-02-09
TWI749504B (zh) 2021-12-11
KR20260018203A (ko) 2026-02-06
IL286492B1 (en) 2026-04-01
JP2025063181A (ja) 2025-04-15
CN115605491A (zh) 2023-01-13
CN115605491B (zh) 2026-03-24
EP3947406A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
JP7621270B2 (ja) シアリダーゼ耐性糖およびその調製および使用方法
US10266502B2 (en) Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
Kondo et al. Glycosyl phosphites as glycosylation reagents: scope and mechanism
WO2015057063A1 (en) Modified glycoprotein, protein-conjugate and process for the preparation thereof
US20250304611A1 (en) Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphate
US9938312B2 (en) Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans
CN105308061A (zh) 经同位素标记的聚糖的合成和用途
Cattaneo et al. Orthogonal cleavage of the 2-naphthylmethyl group in the presence of the p-methoxy phenyl-protected anomeric position and its use in carbohydrate synthesis
Hribernik et al. One pot synthesis of thio-glycosides via aziridine opening reactions
Swarts et al. Chemical synthesis and functionalization of clickable glycosylphosphatidylinositol anchors
WO2024053574A1 (ja) 新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法
EP3097200A1 (en) Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
Xia et al. Total synthesis of sialylated and sulfated oligosaccharide chains from respiratory mucins
Ogawa et al. Synthesis of Ether‐and Imino‐Linked Octyl N‐Acetyl‐5a′‐carba‐β‐lactosaminides and‐isolactosaminides: Acceptor Substrates for α‐(1→ 3/4)‐Fucosyltransferase, and Enzymatic Synthesis of 5a′‐Carbatrisaccharides
Robina et al. Glycosylation Methods in Oligosaccharide Synthesis. Part 1
WO2022191313A1 (ja) 糖鎖及び糖鎖を含む医薬品の製造方法
JP6198207B2 (ja) 新規糖供与体及びそれを用いた糖鎖の合成方法
CN106632518B (zh) 一种鬼臼毒素4-oh衍生物的制备方法
EP1097163A4 (en) IMPROVED GLYCOSYLATION PROCESS USING SULFOXIDE DONORS
CN1334268A (zh) 一种可作药用的阿拉伯－半乳多糖的活性四糖片段的合成
Wu S nthesis and immunological e aluation of Pel and Psl gl cocon ugate accine candidates against Pseudomonas aeruginosa
Rodebaugh et al. TCP Building Blocks for Oligosaccharide Synthesis: Progress Towards the Synthesis of Nodulation Factors
Chopra et al. STATEMENT OF CONTRIBUTION TO CO-AUTHORED PAPER (In Communication)
Yu et al. FÜ R MEINE ELTERN
JPWO2017154938A1 (ja) 硫酸基および／またはリン酸基を有する糖の製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250114

R150 Certificate of patent or registration of utility model

Ref document number: 7621270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02